Chronic inflammation is a key driver of cancer development. Nitrite levels, which are regulated by inducible nitric oxide synthase (iNOS), play a critical role in inflammation.
epithelial cells have been shown to express iNOS in normal and pathological conditions. It has been widely reported that inflammatory stimuli and infectious diseases trigger the production of NO in micromolar concentrations (Griffith & Stuehr, 1995) . iNOS plays an important role in angiogenesis, and collagen deposition. Hemoglobin content, VEGF levels and the number of vessels were decreased in implants in iNOS −/ − mice compared with WT mice (Cassini-Vieira et al., 2015) . The role of iNOS expression in tumors and the adjacent inflammatory microenvironment has been documented as seen with a strong iNOS expression in prostate tumor cells, whereas normal and hyperplastic prostate tissue exhibited weak or no iNOS expression (Aaltoma, Lipponen, & Kosma, 2001 ).
Lipopolysaccharide (LPS) is a bacterial toxin that interacts withTolllike receptor 4 (TLR4) to trigger inflammatory response. LPS-induced systemic inflammation is a classic animal model in studying inflammatory diseases (Juskewitch et al., 2012; Thomas, 1954) . Studies of LPS have focused on the roles of macrophages and mediators, e.g. cytokines, released from those cells during the host response. The effects of LPS resulting in an inflammatory cascade demonstrated by early production of pro-inflammatory cytokines have been shown in vitro and in vivo (Terenzi et al., 1995) . LPS induces iNOS along with several other proinflammatory cytokines, such as tumor necrosis factor-α (TNF-α) and interleukin (IL)-1β (Melillo, Cox, Biragyn, Sheffler, & Varesio, 1994) .
Quantitative approaches using indirect response models (IDR) and receptor mediated-models have been used to describe the effects of LPS on pro-inflammatory markers (Foteinou, Calvano, Lowry, & Androulakis, 2009; Yang, Calvano, Lowry, & Androulakis, 2011) . In one study, a PKPD modeling approach was used to quantify the pharmacodynamics of lung iNOS mRNA expression and plasma NO after LPS-induced acute inflammation in the rats dosed with methylprednisolone (MPL), a well-known anti-inflammatory agent, showed induction of iNOS expression post LPS administration. In the animals that received MPL along with LPS, iNOS expression was significantly lowered which was quantitatively described using an IDR (Sukumaran, Lepist, DuBois, Almon, & Jusko, 2012) .
Curcumin, a well-studied anti-inflammatory and anti-oxidant dietary phytochemical is a component of the rhizomes of turmeric (Curcuma longa), is used in traditional medicine in India (Ammon & Wahl, 1991) . We and others have demonstrated the potential role of curcumin in the regulation of epigenetic modifying genes, thus playing a crucial role in the prevention of several cancers Link et al., 2013; Shu et al., 2011) . The role of curcumin as an antiinflammatory agent and its ability to inhibit the expression of proinflammatory markers such as cyclooxygenase-2 (COX-2), iNOS, TNF-α and interleukin-6 (IL-6) have been well studied (Boyanapalli et al., 2014; Brouet & Ohshima, 1995; Rao, 2007) . Curcumin, diacetylcurcumin and diglutarylcurcumin exhibited potent anti-inflammatory properties compared with aspirin in a carrageenan-induced paw edema model in vivo (Jacob, Badyal, Bala, & Toloue, 2013) .
Curcumin decreases tyrosine phosphorylation in RAW 264.7 murine macrophages by inhibition of ERK 1/2 activation, reducing iNOS enzyme activity, suggesting that curcumin promotes the ubiquitination and degradation of iNOS following LPS stimulation (Ben et al., 2011) .
The epigenetic modulatory role of curcumin has recently been established, with several studies showing that curcumin can inhibit several DNA methyltransferases (DNMTs) and histone deacetylases (HDACs) and thus reverse the silencing of key genes, such as Neurog1, DLEC1, and Nrf2 (Guo, Shu, Zhang, Su, & Kong, 2015; Khor et al., 2011; Shu et al., 2011) . Curcumin elicits anti-inflammatory effects by restoration of the expression of an epigenetically silenced gene called Neprilysin (NEP) that inhibits Akt signaling in Alzheimer's disease (Deng et al., 2014) . The present study aimed to quantitatively describe the effect of curcumin on LPS-induced inflammation using a PK/PD modeling approach.
| MATERIALS AND METHODS

| Chemicals and reagents
Curcumin (98%), isorhamnetin (> 95%, used as internal standard), lipopolysaccharide (LPS), ethanol (99%), diisopropyl ether (98%), ammonium acetate (99%), and formic acid (98%) were purchased from Sigma-Aldrich (St Louis, MO). Acetonitrile (ACN) and pure water for the LC mobile phase were purchased from Honeywell Burdick & Jackson (Muskegon, MI). Deionized water was obtained from a Milli-Q system (Millipore, Bedford, MA). Heparin sodium injections (1000 U/ml) and sodium chloride injections (0.9%) were purchased from Baxter Healthcare Corporation (Deerfield, IL) and Hospira Inc. (Lake Forest, IL), respectively. FicollPaque™ PREMIUM 1.084 was purchased from GE Healthcare (Piscataway, NJ).
| Animals
Female Sprague-Dawley rats weighing 250-300 g with a cannulated jugular vein were purchased from Hilltop Laboratories (Scottsdale, PA). The rats were housed in the Laboratory Animal Service facility at Rutgers University and had free access to food and water. The rats were acclimatized for 3 days, during which they were fed the AIN-76A antioxidant-free diet (Research Diets Inc., New Brunswick, NJ). The experiments were performed in accordance with a protocol approved by the Institutional Animal Care and Use Committee of Rutgers University.
| Dosing of animals, plasma collection, and lymphocyte isolation
On the day of the study, the cannula was removed and connected to polyethylene tubes using adapters (Instech Laboratories, PA) for dosing and blood collection. Heparinized saline (50 U/ml) was used to flush the cannulae and tubes. Rats (n = 6) were administered Curcumin 40 mg/kg (final injection volume of 0.2 ml) in a vehicle consisting of Cremophor, Tween 80, ethanol and water (1:1:1:7) and LPS 50 μg/kg in PBS. LPS 50 μg/kg was administered (n = 6) or vehicle control (n = 4) were administered intravenously through the jugular vein. Blood samples (0.3 ml) were collected at 0, 10, 20, and 30 min and 1, 2, 3, 4, 6, 8 12 and 24 hours after the administration of LPS alone or LPS after curcumin, followed by injection of an equal volume of saline All blood samples were immediately centrifuged at 2500 rpm at 4°C to obtain plasma samples, which were stored at −80°C until analysis. Due to the limited amount of blood withdrawn from the rats at each time point, the blood cells obtained at the same time point were pooled and re-suspended in a 4×volume of Hank's balanced salt solution (HBSS, Invitrogen, Grand Island, NY) . Lymphocytes were isolated using Ficoll-Paque™ PREMIUM 1.084 according to the manufacturer's instructions, and the cell pellets were stored at −80°C until further analysis.
| Sample preparation and liquid chromatographymass spectrometry analysis of curcumin in plasma
Aliquots of original or diluted rat plasma samples (100 μl) spiked with isorhamnetin as an internal standard were extracted twice with 200 μl of extraction solvent (diisopropyl ether: ethanol = 90:10, v/v) , and the layers were separated by centrifugation at 10,000 rpm for 2 min at room temperature. The upper organic layer was transferred to a clean microcentrifuge tube. The combined organic extracts were dried using a vacuum pump, and the dried sample was reconstituted in 200 μl of ACN and water (50:50, v/v) . The reconstituted samples were centrifuged at 17,500 rpm for 5 min at 18-20°C, and the supernatant was collected for analysis.
Liquid chromatography-mass spectrometry (LC-MS) analysis was performed using a Finnigan LTQ (Thermo Fisher Scientific Inc., San Jose, CA) consisting of a Surveyor quaternary pump with a built-in degasser, a Surveyor auto-sampler, and a Surveyor PDA detector. 
| Measurement of mRNA expression in lymphocytes
Total RNA was extracted from lymphocytes using Picopure RNA isolation kits (Life Technologies) and was reversed transcribed into cDNA.
Quantitative PCR was performed using Power SYBR Green mix on an ABI Prism 7900HT system (Applied Biosystems, Foster City, CA).
The relative gene expression was calculated using the ΔΔCt method and β-actin was set as the reference gene for normalization.
| Pharmacokinetic (PK) and pharmacodynamic (PD) modeling
The noncompartmental analysis (NCA) was conducted on the timecourse of curcumin concentration in plasma. Selected pharmacokinetic (PK) parameters were estimated. The area under the concentrationtime curve (AUC) was determined using the linear trapezoidal rule.
Clearance (CL) was calculated by dividing the dose by the AUC. The (1) and (2).
The inter-compartmental clearance between the central (C) and peripheral (P) compartments is represented by CL d ; CL is the elimination from the central compartment; and the amount of curcumin in the central and peripheral compartments is represented by X 1 and X 2 , respectively.
The pro-inflammatory gene expression (iNOS, TNF-α and IL-6) was used as a measure of PD (R) and is described using an indirect response model (Dayneka, Garg, & Jusko, 1993; Sun & Jusko, 1998) .
The differential equations shown in Equation (3) (1) and (2) describe the PK while Equations (4) to (8) explain the PD for iNOS, IL-6 and TNF-α gene expression.
FIGURE 1 Schematic of the integrated PK-PD model for the curcumin-mediated suppression of LPS-induced iNOS expression. The simple indirect model is defined by Equations (1)- (3) in the text
K in represents the zero-order rate constant for the production of the iNOS mRNA, K out denotes the first-order rate constant for the degradation of the iNOS mRNA, and R is assumed to be stationary and arbitrarily set as 1 in the initial condition. The stimulation of iNOS mRNA is triggered by (1 + K lps ), and the duration (T) is fixed for 3H, as observed from the LPS stimulation in all animal groups. The maximum inhibition (I max ) iNOS mRNA by curcumin was fixed at 1 described in Equation (3).
The indirect response model with transit compartments is described by Equations (4)- (8), where K 1 is the rate constant representing the rate of change of LPS, τ represents the mean transit time between compartments, M n represents the response in the transit compartments and K in represents the zero-order rate of formation of the iNOS mRNA. I max is the maximum ability of curcumin to inhibit K in , and IC 50 represents the concentration of curcumin that results in 50% of the maximum inhibition of iNOS. I max was a fixed parameter
(1). The PK/PD modeling was conducted sequentially, where the PK parameters were estimated in ADAPT5 using a generalized least squares method; then, fixing the PK parameters, the gene expression data for LPS alone and in combination with Curcumin were fit to estimate the PD parameters. 
| Pharmacokinetics of curcumin
The concentration-time profiles of curcumin in plasma are displayed in Figure 3 . The results of noncompartmental analysis are listed in 
| Gene expression by qRT-PCR
The expression of pro-inflammatory genes such as iNOS, TNF-α and IL-6 increased over time in the LPS-dosed group and reached a maximum at approximately 3 or 4 h. The expression levels of the epigenetic modulatory genes DNMT3A, HDAC2, HDAC3 and HDAC4 (Figure 4) also increased and reached maximum levels at approximately 4 h which were inhibited over time in the animals dosed with curcumin and LPS (Figure 7) . A PK/PD modeling approach was used to describe quantitatively the modulation of pro-inflammatory gene expression.
| Pharmacokinetic-pharmacodynamic correlation
The expression of pro-inflammatory genes such as iNOS, IL-6 and TNF-α was measured by qRT-PCR. Using an IDR with and without transit compartments, the gene expression profile was quantitatively described. The fold changes in mRNA expression levels were calculated for iNOS, TNF-α, and IL-6 mRNA following treatment with LPS alone or curcumin and LPS. iNOS (Figures 5 and 6 ), TNF-α (Figure 7 a), IL-6 (Figure 7b ) gene expression was induced by LPS treatment, however, the LPS induced pro-inflammatory gene expression was suppressed in animals administered curcumin. The estimated PD parameters for iNOS, IL-6 and TNF-α are presented in Tables 2 and 3 .
| DISCUSSION
Curcumin is an anti-inflammatory agent with potential applications in the prevention of inflammation because inflammation is a precursor to several diseases, such as cancers and neurological disorders (Boyanapalli & Tony Kong, 2015; Deguchi, 2015) . The low oral bioavailability of curcumin is one challenge that must be overcome for the drug to reach adequate circulating levels and to induce a pharmacodynamic (PD) response (Gutierres et al., 2015) . Several studies have attempted to improve the bioavailability of curcumin by adding compounds such as piperine to the formulation (Jager et al., 2014; Klickovic et al., 2014; Shoba et al., 1998) . The ability of curcumin to inhibit DNA hypermethylation and to reactivate the expression of key genes such as DLEC1 and NEP, that are responsible for preventing cancers and neurological disorders establishes it as a potential epigenetic modulator (Deng et al., 2014; Guo et al., 2015; RodriguezParedes & Esteller, 2011) . The role of epigenetic modulators in inflammation is an interesting area of research with the link between them not yet fully understood. Activated IL-6 signaling is known to be responsible for induction of DNMT 1 and 3B in ulcerative colitis and oral cancers, respectively (Chen, Chen, & Lin, 2014; Li et al., 2012) . Nishida et al., 2004) . Studies have shown that Trichostatin-A, a well-known HDAC inhibitor, reduced joint swelling due to hyperacetylation of p21 promoter that was accompanied by reduced TNF-α expression (Chung et al., 2003) . Our results showed that LPS induced HDAC and DNMT gene expression which was inhibited by co-administration with curcumin. The same effects were also seen in the pro-inflammatory cytokines. Although several studies have reported the role of epigenetic modulators such as DNMTs and HDACs on pro-inflammatory genes, the link to the epigenetic modulation and inflammatory gene expression and the subsequent post transcriptional events remain to be clearly understood (Wang et al., 2018) .
A recent study showed that sulforaphane (SFN), a HDAC inhibitor that was shown to inhibit HDACs and to induce Nrf2, has inhibited HDAC gene expression levels upon induction with LPS thereby paving the way to study the epigenetic modulation of LPS induced innate immune responses (Qu et al., 2015) . In this study, the plasma concentration of curcumin and pro-inflammatory as well as epigenetic regulatory gene expression was measured in lymphocytes. The concentration-response of curcumin in lowering acute inflammation following LPS administration was quantitatively described using PK/PD modeling. However, keeping in context the lack of physiological relevance in using the transit compartments in PK/PD modeling to quantitatively describe the epigenetic modulations, the model was not used to describe the epigenetic modulatory gene expression.
Curcumin disposition in plasma exhibited a bi-exponential decline, as described by a two-compartment model with linear clearance (Figure 3) . The PK results indicated high clearance and an increased distribution volume, suggesting an extensive tissue distribution of curcumin. iNOS and TNF-α mRNA expression increased upon LPS dosing after an initial delay of 1 h, with maximum expression at 3 h.
The administration of both curcumin and LPS reduced the expression of iNOS mRNA, which exhibited a peak at 3 h and was considerably lower than the levels elicited by LPS administration alone. Treatment 120 mg/m 2 (~200 mg dose, multiplied by population average body surface area) appeared to be safe (Storka et al., 2015) . On the other hand, as evidenced from clinical trials and dose escalation studies, oral administration of 12,000 mg curcumin is well-tolerated in humans (Lao et al., 2006) . By changing the formulation to improve the bioavailability of curcumin, a maximum plasma concentration of approximately 300 ng/ml was observed after a non-toxic oral dose of 210 mg curcumin in human (Kanai et al., 2012) . This concentration is much higher than the IC 50 estimates of the curcumin antiinflammatory effect in our current model. Therefore, it is likely that a similar inhibitory response of inflammatory genes may be achievable in humans.
In conclusion, the current results are indicative of the effect of curcumin in reducing LPS induced pro-inflammatory gene expression and in modulating the expression of epigenetic regulatory genes. Furthermore, the description of iNOS and TNF-α expression by the PD model suggests that these two genes may be good potential PD markers for future trials studying the anti-inflammatory effects of curcumin. 
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